Introduction
============

Aseptic loosening of total joint replacement is one of the major reasons for long term failure of arthroplasty ([@B26]). Various studies have been performed to understand the mechanisms of aseptic loosening. The local osteolysis surrounding the prosthesis is initiated by an aseptic inflammatory response after incorporation of wear particles by macrophages. Via cytokines macrophages stimulate the proliferation and differentiation of precursor osteoclasts into mature osteoclasts and fibroblasts producing a benign local granulomatous tissue. This process results in implant instability requiring expensive revision surgery. We have recently published two articles about the influence of apoptosis ([@B17]; [@B18]) and neuropeptides (i.e. alpha - Calcitonin-Gene Related Peptide (CGRP) ([@B27]) in aseptic loosening.

Firstly, apoptosis is an important process to regulate homeostasis in tissue. The proliferation and apoptosis in normal tissue is controlled by a variety of proteins of the Bcl-2 family ([@B6]) consisting of different regulators which can block or accelerate the apoptosis ([@B16]). The founding member of this family, Bcl-2 itself, is an inhibitor of apoptotic cell death and can act in both antiapoptotic and antiproliferative manners ([@B8]). Recently we showed a slight reaction using Bcl-2 antibodies in immunochemistry with macrophages and giant cells in granulomatous tissue in loosened arthroplasties and concluded that it is most likely that wear debris induced apoptotic reactions ([@B17]). The *BCL2*gene is located on chromosome 18q21.3 ([@B24]; [@B28]). It consists of three exons and two promoters. These two promoters have distinct functions. Activation of the promoter P2 decreases the activity of the other promoter P1, therefore acting as a negative regulatory element ([@B4]). Park et al. have identified a common single nucleotide polymorphism (SNP, -938C \> A (rs 2279115)) in the inhibitory P2 promoter of the *BCL2*gene ([@B22]). Nückel et al. showed that this polymorphism has functional properties and alters the promoter activity of P2 and inversely the activity of P1 ([@B20]). Furthermore this SNP has been repeatedly associated with different diseases ([@B2]; [@B7]).

Secondly, a possible influence of the nervous system on particle induced osteolysis was shown by Ahmed et al. They found alpha-CGRP-immunoreactive nerve fibres at the interface membrane of arthroplasty. Alpha-CGRP is a neurotransmitter produced by the central and peripheral nervous system and can be found in all tissues surrounding joints and close to the epiphyseal plate, indicating that alpha-CGRP has a function in bone remodelling ([@B14]). Our study group recently demonstrated the impact on particle induced osteolysis in alpha-CGRP knock-out mice ([@B27]). Therefore we focused on the *CALCA*gene (11p15.2p15.1), encoding both alpha-CGRP and Calcitonin. Calcitonin is nearly exclusively produced by thyroid cells ([@B15]; [@B1]; [@B23]). This polypeptide consisting of 32 amino acids plays a role in calcium haemostasis by the inhibition of osteoclasts. However, its physiological function is not clarified in all details ([@B13]). The *CALCA*gene consists of one promoter and six exons. *CALCA*polymorphisms have been examined in many different diseases ([@B25]; [@B5]; [@B12]; [@B11]; [@B19]). Two common polymorphisms - *CALCA*1786T \> C (rs3781719) and -1752C \> G (rs1553005) - in complete linkage are located in the promoter region. Goodman et al. showed a strong association of these *CALCA*polymorphism with the risk of ovarian cancer among some subgroups ([@B11]).

The aim of this study was to investigate the possible influence of the functional *BCL2*(-938 C \> A) and *CALCA*(-1786T \> C) polymorphisms on aseptic loosening of total hip replacement.

Materials and methods
=====================

Patients
--------

Our collective consisted of 87 Caucasian patients of German ancestry operated for aseptic loosening of prosthetic hip joints at the Department of Orthopaedic Surgery (Medical Faculty, University of Duisburg-Essen, Germany). For all patients strict inclusion and exclusion criteria were applied. Entry criteria for this study were the clinical, radiological and intra-surgical diagnosis of aseptic loosening after total hip arthroplasty due to primary osteoarthritis. Exclusion criteria were any deep infection or the suspicion of implant infection, traumatic loosening, inflammatory diseases or intake of immunosuppressant agents after total hip arthroplasty in the patient\'s history. In 36 of 87 cases we performed a revision of the stem and the cup, in 24 of 87 cases only the stem and in 27 cases of 87 only the cup. The present study was performed according to the Declaration of Helsinki and approved by the local Ethics Committee of the University Hospital of Essen.

Determination of *BCL2*and *CALCA*genotypes
-------------------------------------------

DNA was extracted from routinely excised granulomatous scared tissue surrounding the prosthesis. Isolation of genomic DNA was performed using a commercially available kit (QIAamp, Qiagen, Hilden, Germany) following the manufacturer\'s instructions. Genotypes of *BCL2*-938C \> A were determined by Slowdown PCR and pyrosequencing as previously described ([@B11]; [@B20]). *CALCA*-1786T \> C genotypes were determined by PCR using the following primers: forward primer 5\'-CGCTGGGCTGTTTCTCACAATAT-3\'; reverse primer, 5\'-GTTAGACAGGAGTTCAATTAC AGTTGGC -3\'. After an initial denaturation at 94°C, 38 cycles of DNA amplification were done using Taq PCR Mastermix (Eppendorf, Hamburg, Germany) at 94°C for 45 seconds, 62°C for 40 seconds, and 72°C for 45 seconds. The 144 bp PCR products were digested using the restriction enzyme BsmAI (NEB, Ipswich, MA) and analyzed on a 2.5% agarose gel. Unrestricted products (144 bp) represent the TT genotype, completely restricted products (115 + 29 bp) represent the CC genotype.

Statistical analysis
--------------------

Kaplan-Meier plots and the log-rank test were used to retrospectively evaluate the time to loosening, dependent on *BCL2*and *CALCA*genotypes, respectively. Kruskal-Wallis test was used for comparison of non-parametric variables where appropriate. Contingency tables and Pearson\'s χ^2^-test were used to compare categorical variables using *BCL2*and *CALCA*genotypes as indicated. ANOVA was used for comparison of continuous variables. The impact of age, BMI, and *BCL2*and *CALCA*genotypes as prognostic factors for time to aseptic loosening were analysed by univariate Cox regression models. Hazard ratios (HR) and 95% confidence intervals (95% CI) were calculated from these Cox regression models. Control for deviation from the Hardy-Weinberg equilibrium was conducted with the public domain program Hardy-Weinberg equilibrium by J. Ott (<http://www.genemapping.cn/util.htm>). Differences were regarded significant at p \< 0.05. Statistical analysis was performed using SPSS 15.0 (SPSS, Chicago, IL, USA) and GraphPad Prism 4.0 (GraphPad Software, San Diego, CA, USA).

Results
=======

In our cohort genotype distributions of *BCL2*938C \> A (CC:22 CA:49 AA:16) as well as *CALCA*1786T \> C (TT:42 TC:35 CC:10) were not significantly different from Hardy-Weinberg equilibrium. Clinicopathological characteristics are shown in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. Age at the first implantation, age at the revision, gender, body weight, body height, Body Mass Index, Paprosky\'s score ([@B21]) (a classification system in grades, based on preoperative x-rays of the bone loss surrounding a loosened implant), first cup with or without cement and first stem with or without cement were not associated with *BCL2*and *CALCA*genotypes, respectively.

###### 

Clinical characteristics and genotype distribution in patients with aseptic loosening

                                         All             BCL-2 genotype   p-value                         
  -------------------------------------- --------------- ---------------- --------------- --------------- -------
  n (%)                                  87              22 (25.28)       49 (56.32)      16 (18.4)       
  Age at implantation (y)                60.18 ± 13.14   58.14 ± 14.06    60.94 ± 13.72   60.69 ± 10.08   0.703
  Age at replantation (y)                69.31 ± 10.27   67.41 ± 12.77    70.04 ± 9.81    69.69 ± 7.79    0.605
  Gender                                                                                                  
   Female (%)                            60 (68.97)      12 (20.0)        35 (58.33)      13 (21.66)      0.182
   Male (%)                              27 (31.03)      10 (37.04)       14 (51.86)      3 (0.11)        
  Weight (kg)                            75.11 ± 17.11   75.88 ± 19.59    76.1 ± 16.65    71.13 ± 15.18   0.592
  Height (cm)                            166.80 ± 8.35   168.09 ± 6.91    166.77 ± 9.13   165.13 ± 7.95   0.563
  BMI (kg/m\_)                           26.86 ± 5.07    26.74 ± 6.04     27.25 ± 4.92    25.9 ± 4.15     0.655
  First cup with cement (n = 83)                                                                          
   no                                    34 (40.96)      6 (17.65)        19 (55.88)      9 (26.47)       0.280
   yes                                   49 (59.04)      14 (28.57)       28 (57.14)      7 (14.29)       
  First stem with cement (n = 80)                                                                         
   no                                    30 (37.5)       4 (13.33)        19 (63.33)      7 (23.33)       0.147
   yes                                   50 (62.5)       16 (32.0)        27 (54.0)       7 (14.0)        
  Acetabular defects (Paprosky) n = 60                                                                    
   I                                     6 (10)          3 (50.0)         2 (33.33)       1 (16.66)       0.479
   II                                    23 (38.83)      5 (21.74)        12 (52.17)      3 (13.04)       
   III                                   31 (51.66)      7 (22.58)        17 (54.84)      7 (22.58)       
  Femoral defects (Paprosky) n = 52                                                                       
   1                                     4 (7.69)        4 (100)          0               0               0.377
   2                                     23 (44.23)      5 (21.74)        14 (60.87)      4 (17.39)       
   3                                     25 (48.08)      8 (32.0)         12 (48.0)       5 (20.0)        

Data are numbers with percentages given in brackets and numbers with standard deviation, respectively. Categorical variables were analyzed by χ^2^statistics. P values were calculated using ANOVA for continuous variables.

###### 

Clinical characteristics and genotype distribution in patients with aseptic loosening

                                         All             *CALCA*genotype   p-value                         
  -------------------------------------- --------------- ----------------- --------------- --------------- -------
  n (%)                                  87              10 (11.49)        35 (40.22)      42 (48.3)       
  Age at implantation (y)                60.18 ± 13.14   54.3 ± 23.17      59.46 ± 10.47   62.19 ± 11.85   0.215
  Age at replantation (y)                69.31 ± 10.27   66.3 ± 13.27      69.0 ± 9.74     70.29 ± 10.02   0.535
  Gender                                                                                                   
   Female (%)                            60 (68.97)      8 (13.33)         27 (45.0)       25 (41.66)      0.182
   Male (%)                              27 (31.03)      2 (7.41)          8 (29.63)       17 (62.96)      
  Weight (kg)                            75.11 ± 17.11   72.36 ± 15.92     72.91 ± 16.83   77.45 ± 17.61   0.781
  Height (cm)                            166.80 ± 8.35   164.5 ± 8.17      166.00 ± 8.31   167.9 ± 8.45    0.828
  BMI (kg/m\_)                           26.86 ± 5.07    26.69 ± 5.04      26.29 ± 4.86    27.37 ± 5.30    0.437
  First cup with cement (n = 83)                                                                           
   no                                    34 (40.96)      2 (5.88)          17 (50.0)       15 (44.12)      0.171
   yes                                   49 (59.04)      8 (16.33)         16 (32.65)      25 (51.02)      
  First stem with cement (n = 80)                                                                          
   no                                    30 (37.5)       2 (6.66)          13 (43.33)      15 (50.0)       0.510
   yes                                   50 (62.5)       7 (14.0)          17 (34.0)       26 (52.0)       
  Acetabular defects (Paprosky) n = 60                                                                     
   I                                     6 (10)          1 (16.66)         2 (33.33)       3 (50.0)        0.880
   II                                    23 (38.83)      2 (8.7)           13 (56.52)      8 (34.78)       
   III                                   31 (51.66)      5 (16.13)         11 (35.48)      15 (48.39)      
  Femoral defects (Paprosky) n = 52                                                                        
   1                                     4 (7.69)        0                 2 (50.0)        2 (50.0)        0.723
   2                                     23 (44.23)      4 (17.39)         9 (39.13)       10 (43.48)      
   3                                     25 (48.08)      2 (8.0)           10 (40.0)       13 (52.0)       

Data are numbers with percentages given in brackets and numbers with standard deviation, respectively. Categorical variables were analyzed by χ^2^statistics. P values were calculated using ANOVA for continuous variables.

Neither time to aseptic loosening nor median time to aseptic loosening showed a significant association with *BCL2*and *CALCA*genotypes (Figure [1](#F1){ref-type="fig"}). Median time to reimplantation due to aseptic loosening was 101 months (range 1-367) for *BCL2*-938 CC homozygous patients, 86 months (range 5-384) for patients heterozygous for *BCL2*-938 and 52 months (range 0-344) for GG genotype carriers (p = 0.543). Kaplan-Meier curve dependent on *BCL2*-938 genotypes showed no significant association (Figure [1A](#F1){ref-type="fig"}, p = 0.985). Following Hazard Ratios (HR) and 95% Confidence intervals (CI) were calculated for *BCL2*-938 genotypes: CA vs. CC HR 0.982, 95%CI 0.59-1.63, p = 0.945 and AA vs. CC HR 1.033, 95%CI 0.54-1.99, p = 0.923. Median time to aseptic loosening for *CALCA*-1786T \> C genotypes was 69 months (range 2357) for CC genotype carriers, 57 months (range 1384) for heterozygous and 82.5 months (range 0-273) for TT homozygous patients (p = 0.772). No association was detectable in *CALCA*-1786 dependent Kaplan-Meier curve (Figure [1B](#F1){ref-type="fig"}, p = 0.378). Hazard Ratios were 0.793, 95%CI 0.50-1.26, p = 0.323 for TC vs. TT and HR 0.647, 95%CI 0.32-1.31, p = 0.224 for CC vs. TT. Additionally performed subgroup analyses for genotype dependent early aseptic loosening(≤ 10 years) and gender differences showed no significant association with genotypes (Data not shown).

![**Time to aseptic loosening based on Kaplan-Meier curves**. (A) Patients based on *BCL2*-938 genotype. (B) Patients based on *CALCA*- 1786 genotype.](2047-783X-14-6-250-1){#F1}

Discussion
==========

Despite multiple studies to understand and treat aseptic loosening, it is still one of the major problems of arthroplasty. The number of potential replacements is limited due to continued loss of bone substance. In contrast to septic loosening or material failure no specific measures are available to reduce the incidence of aseptic implant loosening until now. Several studies aimed to determine risk factors to detect patients at higher risk who may benefit from prophylactic regimens before implantation, e.g. weight reduction, or pharmacological prophylaxis after implantation. More precise prediction of the individual risk would facilitate to make clinical decision. Unfortunately, clinical parameters for aseptic loosening have yielded partly inconclusive results, e.g. age ([@B3]; [@B10]). It is commonly believed that genetic host factors can influence the incidence and course of aseptic loosening. Recent in-vivo studies of our research group showed the genetic influence on aseptic loosening in knock out mice ([@B27]). Therefore, the aim of the present study was to investigate whether a genetic host factor can be found in humans.

The common *BCL2*-938 and *CALCA*-1786 polymorphisms in the genes *BCL2*and *CALCA*may influence time to aseptic loosening in patients with hip joint replacement and could be used as prediction for time of loosening. Firstly, *BCL2*was found in the key cells of particle induced osteolysis (macrophages, lymphocytes) in loosened arthroplasties ([@B17]) and may have an impact in bone metabolism.

Secondly, the *CALCA*gene is of great importance for the bone metabolism obviously seen in the phaenotype of increased bone formation rate in *CALCA*knock out mice. Furthermore we could show higher rates of particle induced osteolysis in alpha-CGRP knock out mice.

All in all, we could not find any significant correlation between time and median time to aseptic loosening and *BCL2*-938 as well as *CALCA*-1786 genotypes. We were not able to compare the genotype distributions of *BCL2*-938 and *CALCA*-1786 with a population of patients with total hip replacement not suffering from aseptic loosening. Therefore we exploratively compared the genotype distributions with a collective of healthy controls witch were comparable with our cohort in age and gender distribution ([@B20]). Interestingly, *BCL2*-938 genotypes showed a significantly different distribution (CC: 21, CA 63, AA 36, p = 0.0416). The *BCL2*-938CC genotype was at highest risk for aseptic loosening, Odds Ratio (OR) CC vs. AA 2.357, 95%CI 1.02-5.46, p = 0.0434 with heterozygous at intermediate risk with OR 1.750, 95%CI 0.87-3.52, p = 0.1138 for CA vs. AA. Although it is too early for conclusions about this association, the detected association would be in line with functional data of this SNP. The A-allele of this polymorphism is associated with increased Bcl-2 expression ([@B20]) causing less apoptosis around the implant which would explain the significance for less aseptic loosing in patient homozygous and heterozygous for the A-allele of the *BCL2*938 SNP. Therefore, this result suggests the *BCL2*938 SNP as an interesting candidate for further studies.

Unfortunately, statistic analysis did not show significances for the *CALCA*SNP in contrast to our previous mammalian study with alpha CGRP knockout mice ([@B5]). On the one hand, this might be mainly due to the control collective and the small number of patients in our study. A larger more homogenous collective might show significant changes and can detect effect from very low penetrance genes. Moreover, conclusions drawn from this study may not be generalised to all patients undergoing hip replacement - because genetic polymorphisms often vary between ethnic groups of patients. On the other hand, it has to be emphasized that the *CALCA*SNP has shown some significant associations in other studies, but - in contrast to the *BCL2*SNP - its functional properties have not been evaluated until now. Caused by our retrospective collective we could not influence slight differences in physical parameters such as implant design, quality of implantation and stress. Aseptic loosening is a multifactorial process caused by foreign body reaction, allergic reaction, particles, cell to cell interaction, hydrostatical pressure, micro movement, body weight, failure of implantation and implant ([@B26]; [@B9]). As different types of arthroplasty show a different extent of osteolysis a genetic analysis should be prospectively undertaken with the same implant type. Asymptomatic patients with the same implant and implantation technique would be a better collective for comparison. Furthermore it can not be ruled out the possibility that other, not yet identified, alterations in genes involved in cell cycle, apoptosis, receptor expression, DNA replication and gene expression may increase the risk of aseptic loosening after total hip replacement.

Therefore prospective, independent studies with strict inclusion criteria have to be undertaken in the future to rule out all factors uncorrelated to genetics. Furthermore, the inclusion criteria for a prospective study should aim at the bone quality. Although, patients with septic and traumatic loosening, rheumatism, intake of immunosuppressants were excluded in our study we did not measure the exact bone quality at implantation and revision, e.g. osteomalacia, osteoporosis, sclerosis and osteopetrosis.

The genetic influence on humans in this multifactorial process could be shown in this analysis.

Until now the outstanding number-one-reason for particle induced osteolysis has not been found and will possibly not be found in the genes either. Definitely, further polymorphisms have to be analysed as a genetic impact on aseptic loosening was obviously and significantly shown in alpha-CGRP knock out mice in our calvarian model. It bears the chance to analyse a genetic impact on particle induced osteolysis.

All in all, this study combined with our results in the mammalian model support the concept of a role of *BCL2*-938 genotypes in aseptic loosening. Further independent and prospective replication studies are necessary to confirm the general validity of our findings, and deduced hypotheses and aim at the *CALCA*-1786 polymorphism for a second time. Additionally, other genes and genetic polymorphisms could play a major role in the interaction of biomaterials and the environment. Research in this field could lead to better understanding of pathomechanisms and secondary improve the results of arthroplasty.
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